The mechanism of receptor-mediated transcytosis (RMT), which is currently considered the brain drug delivery technology with the greatest potential, is beneficial because substrate-specific brain delivery of molecules of various sizes is possible while maintaining the homeostasis of the blood–brain barrier (BBB). On the other hand, this mechanism has limitations with respect to the amount of material that can be delivered, as there is room for improvements in efficiency, and the excessive distribution to organs other than the brain, and these restrict its generality.
The client seeks a brain drug delivery technology that has the same advantages as the RMT mechanism while overcoming its disadvantages. Ultimately, the client anticipates applying the proposed technology not only to small molecules but also other modalities, such as nucleic acids, peptides, and proteins.
A technology to improve the delivery efficiency of the RMT mechanism or control the distribution to other organs and so improve brain delivery efficiency is also eligible.